News

Highlights from ASH 2018: Research Update
The 2018 annual meeting of the American Society of Hematology (ASH) featured the latest scientific updates, including advances in treatment and new insights in amyloidosis. (more…)
Read More
NICE appraisal for amyloidosis
NICE issue initial negative decisions on inotersen and patisiran
The UK’s National Institute for Health and Care Excellence (NICE) has published Evaluation Consultation Documents on its assessments of inotersen and patisiran. (more…)
Read More
Dena Heath support group leader
14 years strong: Northern California patient support group
On October 20th the Northern California Amyloidosis Support Group celebrated it’s fourteenth year with a meeting held at Stanford’s Blake Wilbur Cancer Center. (more…)
Read More
Tegsedi (Inotersen) approved by FDA for hATTR amyloidosis
The U.S. Food and Drug Administration today approved Tegsedi (inotersen), a novel therapy for the treatment of hereditary TTR amyloidosis polyneuropathy. (more…)
Read More
cardiac amyloid is often misdiagnosed.
Cardiac Amyloid takes center stage at HFSA
For many years, cardiac amyloid has had a few remarkable champions, preaching to half-empty rooms at medical conferences. Well, all that has changed. (more…)
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization